ReviewBiomedicines2022
Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery in Neurodegenerative Disorders.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies-A Systematic Review.Phytotherapy research : PTR · 2026Pooled it
- Optimized mucus adhesion and penetration of lipid-polymer nanoparticles enables effective nose-to-brain delivery of perillyl alcohol for glioblastoma therapy.Drug delivery and translational research · 2026Article
- Brain-targeted intranasal aripiprazole via modified chitosan nanoparticles: controlled release, pharmacokinetics, and pharmacodynamics.Drug delivery and translational research · 2026Article
- Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.International journal of pharmaceutics · 2026Article
- Advances in Nose-to-Brain Delivery Systems for Effective Alzheimer's Disease Management.Current Alzheimer research · 2026Review
- Micro/Nanoparticles in the Nose-Brain Axis: Implications for Pathogenesis and Therapeutic Interventions.International journal of nanomedicine · 2026Review
- Nanotherapeutics Mediated Intranasal Delivery for Therapeutic Effect on Parkinson's Disease: Balancing Advancements and Challenges.Current drug research reviews · 2026Review
- Nanomedicine Solutions for Alzheimer's Disease: A Critical Review of Therapeutic Nanoparticle Strategies.ACS omega · 2025Review
- Revolutionizing Parkinson's treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy.Drug delivery and translational research · 2025Review
- Nasal Residence Depending on the Administered Dosage Form: Impact of Formulation Type on the In Vivo Nasal Retention Time of Drugs in Rats.Pharmaceutics · 2025Article
- Rational development of fingolimod nano-embedded microparticles as nose-to-brain neuroprotective therapy for ischemic stroke.Drug delivery and translational research · 2025Article
- In Vitro Evaluation of the Efficient Passage of PLGA-Formulated Trastuzumab for Nose-to-Brain Delivery.Pharmaceutics · 2025Article
- Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Serum Albumin in Nasal Drug Delivery Systems: Exploring the Role and Application.Pharmaceutics · 2024Review
- Enhancing Acute Migraine Treatment: Exploring Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for the Nose-to-Brain Route.Pharmaceutics · 2024Review
- Alzheimer's Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions.International journal of molecular sciences · 2024Review
- Research progress on intranasal treatment for Parkinson's disease.Neuroprotection (Chichester, England) · 2024Review
- Comparative Analysis of Micrometer-Sized Particle Deposition in the Olfactory Regions of Adult and Pediatric Nasal Cavities: A Computational Study.Pharmaceutics · 2024Article
- Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery.Polymers · 2024Article
- Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals.Beilstein journal of nanotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders (NDs) have become a serious health problem worldwide due to the rapid increase in the number of people that are affected and the constantly aging population. Among all NDs, Alzheimer's and Parkinson's disease are the most common, and many efforts have been made in the development of effective and reliable therapeutic strategies. The intranasal route of drug administration offers numerous advantages, such as bypassing the blood-brain barrier and providing a direct entrance to the brain through the olfactory and trigeminal neurons. The present review summarizes the available information on recent advances in micro- and nanoscale nose-to-brain drug-delivery systems as a novel strategy for the treatment of Alzheimer's and Parkinson's disease. Specifically, polymer- and lipid-base micro- and nanoparticles have been studied as a feasible approach to increase the brain bioavailability of certain drugs. Furthermore, nanocomposites are discussed as a suitable formulation for administration into the nasal cavity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.